Author: Feng, Mei; Pan, Yisheng; Kong, Ruirui; Shu, Shaokun
Title: Therapy of primary liver cancer Cord-id: wdp68onm Document date: 2020_8_10
ID: wdp68onm
Snippet: Abstract Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the rate of incidence is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC (cHCC-ICC). These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and cli
Document: Abstract Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the rate of incidence is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC (cHCC-ICC). These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed.
Search related documents:
Co phrase search for related documents- accurate diagnosis and liver cancer: 1, 2
- accurate diagnosis and liver carcinoma: 1, 2
- accurate diagnosis and liver disease: 1, 2, 3, 4, 5
- liver disease and local regional therapy: 1
Co phrase search for related documents, hyperlinks ordered by date